文献速递肝病

实体器官移植后戊型肝炎二十年单中心回顾性分析

Two decades of hepatitis E in solid organ transplantation: A retrospective monocentric analysis.
PubMed 文献 · Hepatology · 2026-04-03

该研究回顾性分析2001至2024年6452例实体器官移植受者,系统筛查戊型肝炎病毒(HEV)感染,诊断228例(3.53%),肝移植者发病率显著更高。HEV诊断后3个月65.1%转为慢性,利巴韦林治疗至血清和粪便HEV RNA完全清除的持续病毒学应答率为91.5%。

要点

  • 实体器官移植受者HEV感染率3.53%,肝移植者发病率最高。
  • 诊断后3个月65.1%发展为慢性肝炎,他克莫司独立关联慢性化。
  • 利巴韦林治疗至血清和粪便RNA清除的持续病毒学应答率达91.5%。

核心结论

  • 实体器官移植受者HEV感染常见,慢性化和肝外并发症风险显著。
  • 利巴韦林仍是治疗基石,个体化延长疗程可改善结局。
  • 对肝酶升高的实体器官移植受者必须筛查HEV。

研究设计与样本

  • 回顾性单中心研究,纳入2001至2024年随访的6452例实体器官移植受者。
  • 肝酶升高时系统筛查HEV,2016年起移植后3和12个月也筛查HEV。

主要发现

  • 228例(3.53%)诊断HEV感染,肝移植受者发病率显著高于其他移植。
  • HEV诊断后3个月,65.1%发展为慢性肝炎,34.9%实现自发病毒清除。
  • 他克莫司使用独立关联慢性化,霉酚酸使用具有保护作用。
  • 利巴韦林治疗至血清和粪便HEV RNA完全清除的持续病毒学应答率为91.5%。
  • HEV相关神经系统表现占2.2%,肾小球疾病占3.9%,常随病毒清除而缓解。

关键数值与推荐

  • HEV感染诊断228例,占6452例的3.53%。
  • 诊断后3个月慢性肝炎比例65.1%,自发清除比例34.9%。
  • 利巴韦林治疗至完全清除的持续病毒学应答率91.5%。
  • HEV相关神经系统表现2.2%,肾小球疾病3.9%。

临床怎么用

  • 对肝酶升高的实体器官移植受者应筛查HEV。
  • 2016年后可考虑移植后3和12个月筛查HEV。
  • 利巴韦林治疗应延长至血清和粪便HEV RNA完全清除。

局限性

  • 回顾性单中心设计可能限制结果外推。
  • 筛查策略随时间变化可能影响发病率评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The awareness regarding HEV infection in solid organ transplant (SOT) has increased over the last few decades after the reports of chronicity and associated complications. The aim of this study was to describe HEV outcome over a long period in a large cohort of patients undergoing SOT. APPROACH AND RESULTS: This retrospective, single-center study analyzed 6452 patients undergoing SOT followed between 2001 and 2024 and systematically screened for HEV in cases of elevated liver enzymes. Since 2016, patients undergoing SOT have also been screened for HEV at 3 and 12 months after transplantation. We assessed the incidence, natural history, treatment, and extrahepatic manifestations. HEV infection was diagnosed in 228 patients (3.53%). The incidence was significantly higher in patients undergoing liver transplant compared to others. At 3 months after HEV documentation, 65.1% developed chronic hepatitis, while 34.9% achieved spontaneous viral clearance. Tacrolimus use was independently associated with chronicity, while mycophenolic acid use was protective. Ribavirin was the main antiviral therapy, achieving a 91.5% sustained virological response rate when treatment was extended until complete serum and stool HEV RNA clearance. A minority of patients required multiple treatment courses or failed therapy, with some developing cirrhosis or dying viremic. Three patients died from decompensated HEV-related cirrhosis. HEV-associated neurological manifestations (2.2%) and glomerular diseases (3.9%) were observed, often resolving with viral clearance. CONCLUSIONS: HEV infection is frequent in SOT recipients, with significant risks of chronicity and extrahepatic complications. Ribavirin remains the cornerstone of treatment, and individualized duration improves outcomes. Screening for HEV is mandatory in patients undergoing SOT with elevated liver enzymes.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kamar N, Abravanel F, Marion O, et al. Two decades of hepatitis E in solid organ transplantation: A retrospective monocentric analysis. Hepatology. 2026. PMID: 41931106. doi:10.1097/HEP.0000000000001762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。